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LETTERS TO THE EDITOR
Comparing loop diuretics in
chronic kidney disease
To the Editor: Vasavada et al [1] recently concluded
that one must administer twice as much oral furosemide
as oral torsemide to induce a similar acute natriuresis
in patients with chronic kidney disease. It is therefore
difficult to understand why the investigators chose to ad-
minister 40 mg of torsemide once a day and 40 mg of
furosemide twice a day in the chronic phase of the study.
Based on their bioequivalency data, one would predict
that each 40 mg dose of furosemide was much less potent
than each 40 mg dose of torsemide. Because of its short
duration of action, doses of furosemide that are too small
to be effective will still be ineffective even if given twice
a day; the first goal of diuretic therapy is to find an effec-
tive single dose [2]. Furthermore, “there were no differ-
ences in [electrolyte] excretion rate profiles between the
diuretics.” Therefore, it is incorrect to assume that bioe-
quivalent single doses (80 mg of furosemide and 40 mg of
torsemide) will still be therapeutically equivalent when
one diuretic is given as a single daily dose while the other
is given in divided doses. In this study, because each 40 mg
dose of furosemide probably induced a smaller natriure-
sis than each 40 mg dose of torsemide, one would pre-
dict that postdiuretic sodium retention was greater with
torsemide than with furosemide. And because torsemide
was given only once a day, these predictions may explain
why neither diuretic induced a fall in body weight. In my
view, the proper comparison would have been to com-
pare bioequivalent doses of furosemide and torsemide,
both given once or both given twice a day.
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Reply from the Authors
The first goal of diuretic therapy is to find a single ef-
fective dose. Dr. Spital’s suggestion to study single bioe-
quivalent doses is justified if our intention is to treat
edematous disorders. Our intention was to examine the
antihypertensive effect of loop diuretics where such large
doses may not be needed. For example, we do not use
low-dose thiazides by first finding a diuretic response.
Similarly, titrating a loop diuretic to body weight, when
using as an antihypertensive in patients with kidney dis-
ease, is not indicated. A slight contraction in extracellular
fluid volume, not overt volume depletion, is important for
blood pressure lowering with diuretics.
Did we use too little a dose of diuretic? Yes, we used
a dose that was low enough such as not to change the
body weight. However, weight loss is not sine qua non of
antihypertensive response. Thus, low dose thiazides that
may not produce changes in body weight are effective in
producing an antihypertensive effect. In fact, when used
with enalapril, 6 mg of hydrochlorothiazide, which has
no diuretic effect, can effectively lower blood pressure
[1]. However, the dose of diuretics used in our study was
not low enough to produce an antihypertensive response,
the primary objective of our study. In this context, both
diuretics were similar in producing on average about
10 mm Hg lowering of systolic blood pressure, despite use
of multiple antihypertensive drugs. These data demon-
strate the bioequivalence with respect to antihyperten-
sive response of the two diuretics.
To answer the question on how diuretics reduce blood
pressure without changing body weight in patients with
chronic kidney disease we have studied changes in body
volume compartments and neurohumoral markers of vol-
ume status in these patients. A follow-up analysis of this
trial is discussed in an accompanying article devoted to
this important issue raised by Dr. Spital.
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